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ABSTRACT
Background: Among the presently available cytotoxic drugs, 
paclitaxel, in combination with doxorubicin and carboplatin, 
come under the highly active therapy for metastatic breast 
cancer. Between the two brands of paclitaxel (Intaxel, which is 
marketed by Fresenius Kabi and Taxol, the original paclitaxel 
which is manufactured by BMS) the similarity has not been 
evaluated in clinical trial settings till date. This prospective, 
controlled, randomized, multicentre, open-label phase IV study 
was planned to compare the safety and efficacy of Intaxel with 
Taxol, when they were used in combination with carboplatin or 
doxorubicin, as a second line treatment for metastatic breast 
cancer.
Methods: Fourty nine eligible patients were randomized to 
receive Intaxel or Taxol with either doxorubicin or carboplatin. 
The patients who had received a prior anthracycline based 
chemotherapy were randomized to the paclitaxel/carboplatin 
arm. The patients were evaluated in three phases i.e. at baseline, 
during the treatment and at follow up for the tumour response, 
the time period till the disease progression and the toxicity. The 
time till the disease progression was assessed by the Kaplan–
Meier method. The continuous and categorical variables were 
assessed by using the ANOVA test and Fisher’s exact test, 
respectively.
Results: After 3 cycles, an objective response rate of 55.56% 
(CR = 3, PR = 7) was noted in the Intaxel group and that of 
59.09% (CR = 1, PR = 12) was noted in the Taxol group. After 
6 cycles, an objective response rate of 50% was noted in 
both the groups. No significant difference was observed in the 
response rate of the two groups after 3 cycles (p > 0.05) and at 
the end of the treatment (p > 0.05). The patients who received 
Intaxel had a lower incidence of thrombocytopaenia (p = 0.0146) 
and neurosensory loss (p = 0.008) as compared to those who 
received Taxol. 
Conclusion: The results of this study demonstrated that the 
safety and efficacy of Intaxel and Taxol are equivalent when 
they are used in combination with other cytotoxic agents as the 
second line of treatment for metastatic stage IV breast cancer.
INTRODUCTION
Breast cancer is one of the most common malignancies which affect 
women all over the world [1-2]. The use of systemic chemotherapy 
in metastatic breast cancer improves the quality of life and it delays 
the disease progression; however, the aim remains largely palliative. 
Among the presently available chemotherapy options; paclitaxel, 
doxorubicin and carboplatin are highly active [3-4].
Paclitaxel was introduced in the 1990s and since then, it has been 
a major focus of the active clinical and laboratory research for its 
optimal integration into new treatment strategies for patients with 
breast cancer [5-6]. With the emergence of the taxanes as one of 
the most effective classes of treatment for breast cancer, clinical 
trials were conducted to determine the efficacy and the safety 
of the anthracycline/taxane combinations [7-9]. Doxorubicin or 
carboplatin, combined with paclitaxel, have shown good efficacy 
in the previously treated patients with metastatic breast cancer [1, 
10-11]. The available data and experiences with the paclitaxel-
based therapy in patients with advanced breast cancer indicate 
that the treatment may cause regression of the tumour and also 
delay the time till the disease progression [10-15].
The US-FDA has approved paclitaxel (Taxol, Bristol-Myers Squibb 
Company; Princeton, NJ) as a second line therapy for advanced 
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metastatic breast cancer. The Dabur Research Foundation (DRF) 
has also introduced the paclitaxel which can be retrieved from 
the leaves of the Himalayan yew tree by using an environment 
friendly manufacturing technique without harming the tree itself. 
The marketing authorization of Fresenius Kabi’s brand of paclitaxel, 
“Intaxel”, was granted by The Drug Controller General of India in 
the year 1994. Subsequent to this, Intaxel has been launched 
successfully in many global markets for the same indications as 
Taxol. 
So far, the equivalence of these two brands has not been evaluated 
in clinical trial settings. This study evaluated the safety and efficacy 
of Intaxel in comparison to those of Taxol. The primary objective 
of this study was to compare the toxicity and efficacy of Intaxel 
with those of Taxol; when they were administered in combination 
with either doxorubicin or carboplatin, as a second line option in 
patients with advanced metastatic breast cancer.
METHODS
Study Design
This was a prospective, randomized, active-controlled, multicentre, 
open-label phase IV parallel group study. This study was approved 
by the Central Ethical Committee and informed written consents 
were obtained from all the patients prior to their enrollment. All the 
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eligible patients were randomized to receive Intaxel or Taxol with 
either doxorubicin or carboplatin. The patients who had received a 
prior anthracycline based chemotherapy were randomized to the 
paclitaxel/carboplatin arm.
Patients
From Apr-2001 to Feb-2003, women with histologically confirmed 
metastatic breast cancer and measurable disease entered this 
study. The patients were declared as eligible if they had received a 
prior treatment with or without anthracyclines. However, the patients 
who received prior paclitaxel were not considered to be eligible. 
Only those patients with the following specifications were included 
in the study: adequate bone marrow and renal, cardiac or liver 
functions which were as follows: WBC > 3000 /mm3, ANC > 2000/
mm3, Platelets > 75,000 /mm3, Hb > 10 g/dl; serum biochemistry 
levels: AST, ALT < 2.5 x upper limit of normal range (ULN); Total 
bilirubin < 1.5 times, ULN Serum Creatinine < 1.5 times, ULN 
Calcium < 10.5 mg/dl; measured or evaluated urinary creatinine 
clearance > 60 ml/min; no signs of respiratory insufficiency; a 
stable cardiac status and heart rhythm and no clinical evidence of 
congestive heart failure or conduction abnormalities. The patients 
were required to have an Eastern Co-operative Oncology Group 
(ECOG) Performance status of 0-2. The patients with metastatic 
Central Nervous System (CNS) disease were excluded.
Treatment Plan
Doxorubicin was administered at a dose of 60 mg/m2 (in 100 ml 
normal saline as a 30 min infusion) on day 1, followed by paclitaxel 
as a 3 hr continuous iv. infusion in 500 ml of normal saline at a 
dose of 175 mg/m2, cyclically on day 1 or 2, every 3 weeks for six 
cycles. The patients who were on carboplatin received paclitaxel 
as a 3 hour continuous iv. infusion in 500 ml of normal saline at a 
dose of 175 mg/m2 on Day 1, once every 3 weeks, followed by 
carboplatin (Area under the Curve; AUC = 4-5, Calvert formula) on 
day 2 in 5% Dextrose, 250 ml over 30 min, cyclically every 3 weeks 
for six cycles. The patients were pre-medicated for paclitaxel as 
per the established regimen. 
The Toxicity and Response Assessments
The tumour response was assessed at the end of the third and six 
cycles by X-ray, computed tomography scans, magnetic resonance 
imaging, or clinical examinations according to the WHO criteria. 
The toxicity was evaluated according to the NCI-CTC version 2.0 
criteria.
STATISTICAl ANAlySIS
The time till the disease progression was calculated from the date 
of enrollment of the women in the study to the date of disease 
progression and it was assessed by the Kaplan–Meier method. 
Statistical analyses were performed by using Fisher’s exact test 
and the ANOVA test. All the tests were two-sided with a 95% 
significance level. The statistical analysis was performed by using 
SAS Proc Mixed, Version 8.2.
RESUlTS
A total of 49 subjects were enrolled in the study and they 
were randomized to four treatment arms as follows: Group 
1a: Intaxel+doxorubicin (n=4); Group 1b: Intaxel+carboplatin 
(n=21); Group 2a: Taxol+doxorubicin (n=4); and Group 2b: 
Taxol+carboplatin (n=20). Forty two patients completed 3 cycles, 
but 2 patients were excluded from the analysis, since their 
radiological data was unavailable and hence, 40 patients were 
assessed for the efficacy of the treatment. Out of the 31 patients 
who completed 6 cycles, 30 were evaluated for the response to 
the treatment due to the unavailability of the data of one patient. 
All the 49 subjects who were enrolled were evaluated for the 
toxicity end points.
The baseline patient characteristics were similar between the 
two paclitaxel study groups. The median age of the patients was 
58.3 ± 9.5 years (range- 27-69 years). Post-menopausal patients 
constituted approximately 92% (n= 45) of the patients who were 
enrolled. The ECOG status and the patients who completed the 
treatment cycles have been presented in [Table/Fig-1].
Efficacy Results
The response to the treatment was evaluated in 40 patients (18 
in the Intaxel group and 22 in the Taxol group) who completed 
a minimum of 3 cycles of chemotherapy, and in 30 patients (14 
in the Intaxel group and 16 in the Taxol group) who completed 6 
treatment cycles. 
After 3 cycles, objective total response rates of 55.6% and 59.1% 
were noted in the Intaxel and the Taxol groups, respectively. At the 
end of 6 cycles, the total response rate was found to be similar 
(50%) in both the groups. There was no difference in the response 
rates of the two groups (p>0.05) at the end of 3 and 6 cycles. The 
response rates have been summarized in [Table/Fig-2].
As shown in [Table/Fig-3] and [Table/Fig-4], the disease progression 
rate was alike between both the treatment groups. The number 
of patients with disease progression were 11 (44%) vs. 9 (37.5%) 
in the Intaxel and the Taxol groups respectively. The median time 
till the disease progression (TTP) for Intaxel was 157 days as 
compared to 222 days in the Taxol group. However, the difference 
was not statistically significant (log rank p=0.3607). 
Intaxel
(group 1; n = 25)
taxol
(group 2; n = 24)
ECOG Grade
 Grade 0 13 15
 Grade 1 10 9
 Grade 2 2 0
Patients completing number of treatment cycles
 3 cycles 19 23
 6 cycles 15 16
[Table/Fig-1]: ECOG status and Treatment cycles in study population
Intaxel
(group 1)
taxol
(group 2)
Number of subjects with evaluable 3 cycles 18 22
 Complete Response (CR) 3 1
 Partial Response (PR) 7 12
 Incomplete Response (IR) 6 6
 Progressive Disease (PD) 2 3
Number of subjects with evaluable 6 cycles 14 16
 Complete Response (CR) 3 2
 Partial Response (PR) 4 6
 Incomplete Response (IR) 4 5
 Progressive Disease (PD) 3 3
[Table/Fig-2]: Response evaluation after three and six cycles of chemotherapy
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[Table/Fig-3]: Kaplan-Meier graph showing disease progression rate 
adverse event 
Intaxel group taxol group
 CtC grade   CtC grade  
grade 1 grade 2 grade 3 grade 4 total grade 1 grade 2 grade 3 grade 4 total 
Alopecia 2 8 2 3 15 (60%) 1 17 1 2 21 (88%)
Asthenia 2 4 6 (24%) 8 3 11 (46%)
Neurosensory loss 1 1 (4%) 5 3 8 (33%)
Nausea 5 5 (20%) 3 3 6 (25%)
Vomiting 1 1 2 (8%) 3 3 (13%)
Myalgia 1 1 (4%) 2 3 5 (21%)
Pain in limbs 1 1 2 (8%) 1 1 2 (8%)
Diarrhoea
 
1 1 1 3 (12%) 1 1 (4%)
Cough 1 1 (4%) 1 1 (4%)
Fever - 3 3 (13%)
Loss of appetite - 2 1 3 (13%)
Headache
 
- 2 2 (8%)
Abdominal pain
 
- 1 1 2 (8%)
Motor Neuropathy - 1 1 (4%)
Nail changes - 1 1 (4%)
Hypersensitivity - 1 1 (4%)
Urticaria - 1 1 (4%)
Skin hyperemia - 1 1 (4%)
Flushing 1 1 (4%) -
Nail pain 1 1 (4%) -
Bone pain 1 1 (4%) -
Tachycardia 1 1 (4%) -
Epistaxis 1 1 (4%) -
Epigastric pain
 
1 1 (4%) -
Somnolence 1 1 (4%) -
Conjunctivitis - 1 1 (4%)
Superficial phlebitis - 1 1 (4%)
Lymphedema
 
- 1 1 (4%)
Aphthous ulcer - 1 1 (4%)
Sacral abscess - 1 1 (4%)
Loss of consciousness - 1 1 (4%)
[Table/Fig-5]: Percentage data of non-hematological adverse events
Intaxel taxol 
Number Randomized 25 24 
No. of subjects with Disease Progression 11 9 
No. of subjects without Disease 
Progression (censored) 
14 (56%) 15(63%) 
Median TTP (days) 157 222 
95% Lower Confidence Interval TTP 
(days) 
122 134 
Hazard Ratio (95% Confidence Limits) 1.525 (0.612, 3.797)
Log-Rank p-values 0.3607
[Table/Fig-4]: Time to Disease Progression (TTP) 
Safety Results 
All the patients who received at least one dose of treatment were 
included in the safety data analysis. Overall, the treatment was 
well tolerated. Only one incidence of hypersensitivity was reported 
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Intaxel group taxolgroup
CtC grade CtC grade
grade 1 grade 2 grade 3 grade 4 total n (%) grade 1 grade 2 grade 3 grade 4 total n (%)
Leukopenia 2 5 9 2 18 (72) 3 9 9 1 22 (92)
Anemia 4 6 3 2 15 (60) 2 4 5 - 11 (46)
Thrombocytopenia 3 1 4 1 9 (36) 11 3 2 1 17 (71)
Neutropenia 5 2 7 4 18 (72 ) - 7 4 7 18 (75)
Lymphocytopenia 1 2 - - 3  (12) 2 - - - 2  (8)
Hematocrit - 1 - 1 2 (8 ) 1 - - - 1 (4)
[Table/Fig-6]: Incidence of hematological Toxicities as per CTC Criteria 
during the study. [Table/Fig-5 and 6] represent the reported non-
haematological and haematological adverse events. A significant 
lower incidence of neurosensory loss was observed in the Intaxel 
group (1/25 vs. 8/24, p = 0.008 for Intaxel vs. Taxol). Similarly, a 
lower incidence of thrombocytopaenia was observed in the Intaxel 
group (9/25) as compared to that in the Taxol group (17/24) (p 
= 0.0146). Other reported toxicities were comparable in both the 
groups.
Five patients in the Intaxel group and three in the Taxol group 
discontinued their treatments due to adverse events. One death 
was reported during the study, which was not related to the 
treatment. This patient was diagnosed with brain metastasis, 3 
days after the first cycle of the therapy. 
DISCUSSION
The introduction of paclitaxel for the treatment of breast cancer led 
to an improvement in the management of advance diseases. The 
inclusion of paclitaxel as a part of the combination chemotherapy 
for metastatic breast cancer has evolved as a standard care, 
especially, due to the good response rate and the increased time 
to progression [15-16]. 
Our study provides evidence that the use of Intaxel in combination 
with docetaxel or carpolatin as a second line treatment regimen 
gives equivalent overall survival advantages to the regimen, which 
includes Taxol. Both Intaxel and Taxol demonstrated comparative 
response rates after 3 and 6 cycles (p > 0.05) The average response 
rate which was achieved in our study patients was 50%-60%. In 
various clinical trials, paclitaxel, in combination with carboplatin or 
doxorubicin for metastatic breast cancer, showed similar response 
rates [11,17-19]. Similar response rates were observed with the 
paclitaxel therapy in metastatic breast cancer patients with and 
without a prior exposure to anthracyclines [14]. 
The TTP rate and the hazard ratio were similar between both the 
treatment groups, thus indicating that Intaxel was equally efficacious 
as Taxol, when it was combined with doxorubicin or carboplatin for 
the second line treatment for stage IV metastatic breast cancer. 
The bias which arises in the investigator or the patient is often a 
concern in open-label studies; however, it is unlikely that such a 
bias occurred in this study in the determination of the efficacy. 
If such biases would have played a role, we would have seen a 
superior betterment in the patients who were treated with the Taxol 
therapy, where the efficacy of the drug has been well established 
in clinical settings.
It was also observed that paclitaxel, in combination with either 
carboplatin or doxorubicin, was well tolerated by the patients. The 
safety profile of paclitaxel in our study was consistent with that of 
the previous reports [20-21]. A majority of the adverse effects which 
were noted in both the groups resolved without intervention and 
they had no further sequel. The majority of the adverse events were 
graded as mild or moderate in nature. The most common adverse 
effects which were observed in both the groups were alopecia and 
asthenia. Though they were not statistically significant, yet, clinically 
a larger number of patients who were on Taxol experienced adverse 
reactions as compared to those in the Intaxel group. 
A statistically higher incidence of neurosensory loss was observed 
in the Taxol (8/24) group as compared to that in the Intaxel group 
(1/25). Also, a higher incidence of haematological toxicities was 
observed with the Taxol treatment as compared to the Intaxel 
treatment. Thus, for the haematological adverse events, Intaxel 
demonstrated a better safety profile as compared to Taxol, with a 
lower incidence of myelo-suppression. The most common adverse 
effect which needed medication was bone marrow toxicity, which 
was controlled with the use of the colony granulocyte stimulating 
factor.
No treatment related deaths were observed. One death was attri-
buted to the disease progression. No cases of cardiotoxicity were 
observed in our study, as in few of the previously published studies 
[22-23]. The difference in the incidences of serious adverse events 
which were observed in both the groups was not statistically 
significant. The numbers of patients who discontinued the therapy 
due to adverse events were similar in both groups. To summarize, 
both the brands of paclitaxel, Intaxel and Taxol, had similar toxicity 
profiles. 
In the present study, the patients who had received a prior 
anthracycline based chemotherapy were randomized to receive 
the carboplatin-paclitaxel combination only. This was done to 
improve the response to the treatment. The number, therefore, of 
the patients in the doxorubicin-paclitaxel group was low. This did 
not introduce any bias in the study, as the patients could still be 
randomized to the paclitaxel study drug (either Intaxel or Taxol). 
However, overall, the small number of patient enrollment was the 
limitation of this study.
CONClUSION 
In conclusion, our study showed a similar efficacy of Intaxel as 
compared to that of Taxol when it was combined with docetaxel or 
carboplatin as a second line treatment for stage IV breast cancer. 
The toxicities which were associated with the treatment were 
manageable. Overall, this study demonstrated that Intaxel and 
Taxol had comparable efficacies and safety profiles for metastatic 
breast cancer.
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